Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA.
Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA.
Toxicology. 2023 Jan 15;484:153394. doi: 10.1016/j.tox.2022.153394. Epub 2022 Dec 13.
Perinatal and neonatal exposure to bisphenol A (BPA) has been linked to enhancement of prostate carcinogenesis in rats induced by combined treatment with estradiol and testosterone, but human data are lacking. This study aimed to determine the effects of perinatal BPA exposure on induction of prostate cancer in rats by sequential treatment with N-methyl-N-nitrosamine (MNU) and continuous low dose administration of testosterone. Pregnant Sprague Dawley rats were exposed to BPA administered by subcutaneous Alzet minipumps at doses of 2.5 or 25 µg/kg body weight/day from gestational day 9 until postnatal day 28 when pups were weaned providing exposure of offspring in utero and via the mother's milk. At 10-12 weeks of age, one male offspring per litter was treated with an intraperitoneal injection of MNU after hormonal stimulation of prostatic cell proliferation followed two weeks later by subcutaneous insertion of Silastic implants containing testosterone until the termination of the study 57-58 weeks after MNU injection. The perinatal BPA exposure did not significantly affect the incidence of prostate carcinomas which was slightly lower in exposed rats (33-23 %) than in control animals (40 %). Carcinomas in all accessory sex glands combined were also insignificantly less frequent in exposed (46-48 %) than in control rats (60 %). The incidence of malignant tumors at any site in the body was significantly lower in exposed rats (81-65 %) than in controls (93 %). In conclusion, perinatal BPA exposure did not significantly modify prostate cancer induction by MNU plus testosterone in rats, unlike the enhancement of prostate carcinogenesis induced by treatments involving estradiol administration. Which of the two models of prostate carcinogenesis is more relevant for the human situation is unclear at present.
围生期和新生儿期接触双酚 A(BPA)已被证实可增强雌二醇和睾酮联合处理诱导的大鼠前列腺癌发生,但目前尚缺乏人体数据。本研究旨在确定围生期 BPA 暴露对 N-甲基-N-亚硝胺(MNU)序贯处理和持续低剂量睾酮给药诱导大鼠前列腺癌的影响。妊娠 Sprague Dawley 大鼠从妊娠第 9 天至产后第 28 天,通过皮下 Alzet 微型泵以 2.5 或 25μg/kg 体重/天的剂量给予 BPA 暴露,以实现胎儿和通过母亲乳汁暴露后代。在 10-12 周龄时,在雄性后代的前列腺细胞增殖受到激素刺激后,对每窝一只雄性后代进行腹腔内 MNU 注射,两周后皮下插入含有睾酮的 Silastic 植入物,直至 MNU 注射后 57-58 周研究结束。围生期 BPA 暴露并未显著影响前列腺癌的发生率,暴露组(33-23%)略低于对照组(40%)。所有附属性腺联合的癌发生率在暴露组(46-48%)也明显低于对照组(60%)。在任何部位发生的恶性肿瘤的发生率在暴露组(81-65%)明显低于对照组(93%)。总之,围生期 BPA 暴露并未显著改变 MNU 加睾酮诱导的大鼠前列腺癌的发生,与涉及雌二醇给药的处理增强前列腺癌发生不同。目前尚不清楚两种前列腺癌发生模型中哪一种与人类情况更相关。